Autofluorescence imaging improves accuracy of wound debridement

The FDA approved crinecerfont (Crenessity) as a first-in-class treatment for classic congenital adrenal hyperplasia (CAH), the agency announced late Friday. Crinecerfont was approved for use

No­var­tis has the go-ahead from the FDA to man­u­fac­ture its ra­dio­phar­ma­ceu­ti­cal Plu­vic­to at a new fa­cil­i­ty in In­di­anapo­lis, mark­ing a step to­ward ad­dress­ing bur­geon­ing de­mand.